Cargando…

Systematic review and network meta-analysis of combination and monotherapy treatments in disease-modifying antirheumatic drug-experienced patients with rheumatoid arthritis: analysis of American College of Rheumatology criteria scores 20, 50, and 70

BACKGROUND: Biologic disease-modifying antirheumatic drugs (bDMARDs) extend the treatment choices for rheumatoid arthritis patients with suboptimal response or intolerance to conventional DMARDs. The objective of this systematic review and meta-analysis was to compare the relative efficacy of EU-lic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Orme, Michelle E, MacGilchrist, Katherine S, Mitchell, Stephen, Spurden, Dean, Bird, Alex
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2012
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3529627/ https://www.ncbi.nlm.nih.gov/pubmed/23269860 http://dx.doi.org/10.2147/BTT.S36707

Ejemplares similares

Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2013)

American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis: 2022 revision
por: Studenic, Paul, et al.
Publicado: (2023)

American College of Rheumatology/EULAR Remission Criteria for Rheumatoid Arthritis: 2022 Revision
por: Studenic, Paul, et al.
Publicado: (2022)

Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritis
por: Cawson, Matthew Richard, et al.
Publicado: (2014)

Comparison of Biological Agent Monotherapy and Associations Including Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis: Literature Review and Meta-Analysis of Randomized Trials
por: Delpech, Célia, et al.
Publicado: (2022)

Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritis
por: Nash, Peter, et al.
Publicado: (2021)

Immunogenicity of Sarilumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant to Disease-Modifying Antirheumatic Drugs
por: Wells, Alvin F., et al.
Publicado: (2019)

Prevalence and development of hip and knee osteoarthritis according to American College of Rheumatology criteria in the CHECK cohort
por: Damen, Jurgen, et al.
Publicado: (2019)

Fibromyalgia diagnostic model derived from combination of American College of Rheumatology 1990 and 2011 criteria
por: Ghavidel-Parsa, Banafsheh, et al.
Publicado: (2019)

Validation of the 2011 and 2016 American college of rheumatology diagnostic criteria for fibromyalgia in a Chinese population
por: Jiao, Juan, et al.
Publicado: (2023)

Quantitative Metabolic Volumetric Product on (18)Fluorine-2fluoro-2-deoxy-D-glucose-positron Emission Tomography/Computed Tomography in Assessing Treatment Response to Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis: Multiparametric Analysis Integrating American College of Rheumatology/European League Against Rheumatism Criteria
por: Kumar, Nandigam Santosh, et al.
Publicado: (2017)

Leflunomide monotherapy versus combination therapy with conventional synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis: a retrospective study
por: Deng, Daihua, et al.
Publicado: (2020)

Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis
por: Hazlewood, Glen S, et al.
Publicado: (2016)

Performance of the New 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria in a Large Unicentric Cohort
por: Gheorghiu, Ana Maria, et al.
Publicado: (2022)

2015 Gout Classification Criteria: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative
por: Neogi, Tuhina, et al.
Publicado: (2015)

2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative
por: Neogi, Tuhina, et al.
Publicado: (2015)

Indirect Treatment Comparison of the Efficacy and Safety of Sarilumab Monotherapy in Rheumatoid Arthritis Patients with Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs
por: Choy, Ernest, et al.
Publicado: (2019)

Central sensitization in opioid use disorder: a novel application of the American College of Rheumatology Fibromyalgia Survey Criteria
por: Hall, O. Trent, et al.
Publicado: (2022)

How to Administer Quinine
por: MacGilchrist, A. C.
Publicado: (1917)

Blackwater Fever, Hæmolysis and Quinine
por: MacGilchrist, A. C.
Publicado: (1909)

Necrosis, and Strong Solutions of Quinine
por: MacGilchrist, A. C.
Publicado: (1917)

Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis
por: Katchamart, W, et al.
Publicado: (2008)

Prevalence of the American College of Rheumatology classification criteria in a group of 162 systemic lupus erythematosus patients from Croatia
por: Cerovec, Mislav, et al.
Publicado: (2012)

Incorporation of Salivary Gland Ultrasonography Into the American College of Rheumatology/European League Against Rheumatism Criteria for Primary Sjögren's Syndrome
por: van Nimwegen, Jolien F., et al.
Publicado: (2020)

Monotreatment With Conventional Antirheumatic Drugs or Glucocorticoids in Rheumatoid Arthritis: A Network Meta-Analysis
por: Guski, Louise S., et al.
Publicado: (2023)

Eligibility criteria for biologic disease-modifying antirheumatic drugs in axial spondyloarthritis: going beyond BASDAI
por: Marona, Jose, et al.
Publicado: (2020)

Factors influencing the use of biologic therapy and adoption of treat-to-target recommendations in current European rheumatology practice
por: Taylor, Peter C, et al.
Publicado: (2018)

Korean College of Rheumatology: Forty Years of Excellence
por: Choe, Jung-Yoon, et al.
Publicado: (2022)

2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative
por: Dasgupta, Bhaskar, et al.
Publicado: (2012)

Prevalence of the American College of Rheumatology hematological classification criteria and associations with serological and clinical variables in 460 systemic lupus erythematosus patients
por: Skare, Thelma, et al.
Publicado: (2015)

Performance of the 2015 American College of Rheumatology/European League against Rheumatism Classification Criteria for Gout in Korean Patients with Acute Arthritis
por: Choi, In Ah, et al.
Publicado: (2019)

Identifying factors associated with concordance with the American College of Rheumatology rheumatoid arthritis treatment recommendations
por: Harrold, Leslie R., et al.
Publicado: (2016)

Rheumatoid arthritis study of the Egyptian College of Rheumatology (ECR): nationwide presentation and worldwide stance
por: Gheita, Tamer A., et al.
Publicado: (2023)

Protective effect of antirheumatic drugs on dementia in rheumatoid arthritis patients
por: Judge, Andy, et al.
Publicado: (2017)

Antirheumatic therapy is associated with reduced complement activation in rheumatoid arthritis
por: Nguyen, Thao H. P., et al.
Publicado: (2022)

Reliability, Factor Structure and Predictive Validity of the Widespread Pain Index and Symptom Severity Scales of the 2010 American College of Rheumatology Criteria of Fibromyalgia
por: Galvez-Sánchez, Carmen M., et al.
Publicado: (2020)

Incomplete Systemic Lupus Erythematosus: What Remains After Application of American College of Rheumatology and Systemic Lupus International Collaborating Clinics criteria?
por: Lambers, Wietske M., et al.
Publicado: (2020)

Correspondence on ‘2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus’ by Aringer et al
por: Cui, Ran, et al.
Publicado: (2022)

Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study
por: Fleischmann, R, et al.
Publicado: (2008)

Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice
por: Bykerk, Vivian P., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_1drch5d64tb3v6k45ej5urnfna